Huakang Biomedical Holdings Company Limited
HKSE: 8622.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Chunguang Zhang
- Employees
- 91
- Headquarters
- Wan Chai, Hong Kong SAR China
- IPO year
- 2018
- Market cap
- HK$170.1M
- Website
- https://www.huakangbiomedical.com
Loading 8622…
Loading profile data…Frequently asked questions about 8622
What does Huakang Biomedical Holdings Company Limited (8622.HK) do?
Huakang Biomedical Holdings Company Limited, an investment holding company, engages in the research, development, manufacture, marketing, and sale of in-vitro diagnostic (IVD) reagents in the People's Republic of China. It offers male and female fertility IVD, parasite antibody detection, and Epstein-Barr virus antibody detection reagents; auxil...
Where does 8622.HK trade?
Huakang Biomedical Holdings Company Limited (8622.HK) trades on the Hong Kong Stock Exchange.
What sector is 8622.HK in?
Huakang Biomedical Holdings Company Limited (8622.HK) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Huakang Biomedical Holdings Company Limited?
Chunguang Zhang is the chief executive officer of Huakang Biomedical Holdings Company Limited (8622.HK).
Where is Huakang Biomedical Holdings Company Limited headquartered?
Huakang Biomedical Holdings Company Limited is headquartered in Hong Kong SAR China.
Does 8622.HK pay a dividend?
Huakang Biomedical Holdings Company Limited (8622.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 8622.HK go public?
Huakang Biomedical Holdings Company Limited (8622.HK) completed its initial public offering in 2018.